作者
Oliver Hendricks, Tonny Elmose Andersen, Afshin Ashouri Christiansen, Jette Primdahl, Ellen Margrethe Hauge, Torkell Ellingsen, Tina Ingrid Horsted, Anja Godske Bachmann, Anne Gitte Loft, Anders Bo Bojesen, Mikkel Østergaard, Merete Lund Hetland, Niels Steen Krogh, Kirsten Kaya Roessler, Kim Hørslev Petersen
发表日期
2019/6/1
期刊
BMJ open
卷号
9
期号
6
页码范围
e028197
出版商
British Medical Journal Publishing Group
简介
Introduction
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic, systemic, inflammatory diseases, primarily in the musculoskeletal system. Pain and fatigue are key symptoms of RA and AS. Treatment presents a clinical challenge for several reasons, including the progressive nature of the diseases and the involvement of multiple pain mechanisms. Moreover, side effects of pain treatment pose an implicit risk. Currently, no well-controlled studies have investigated how medical cannabis affects pain and cognitive functions in RA and AS. The present study aims to evaluate the efficacy and safety of medical cannabis in the treatment of persistent pain in patients with RA and AS with low disease activity.
Methods and analysis
A double-blinded, randomised, placebo-controlled study of cannabidiol (CBD), followed by an open label add-on of tetrahydrocannabinol (THC) with collection of clinical data and …
学术搜索中的文章
O Hendricks, TE Andersen, AA Christiansen… - BMJ open, 2019